CytRx News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.09.20	CCXI To Face FDA In April, CRDF Soars On Colorectal Cancer Trial Data, VCNX In Deal With MRK (RTTNews)
07.06.18	CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data Presented at the American Society of Clinical Oncology 2018 Annual Meeting (PR Newswire)
04.06.18	CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR™ Albumin Binding Ultra-High Potency Oncology Drug Candidates (PR Newswire)
30.05.18	CytRx Corporation to Present at 8th Annual LD Micro Invitational Conference (PR Newswire)
17.05.18	CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Clinical Data to be Presented at the American Society of Clinical Oncology 2018 Annual Meeting (PR Newswire)
08.05.18	CytRx Reports First Quarter 2018 Financial Results (PR Newswire)
07.05.18	CytRx Corporation to Present at OneMed NYC Oncology Investor Conference 2018 (PR Newswire)
03.05.18	CytRx Corporation Names Eric L. Curtis as Its President and Chief Operating Officer (PR Newswire)
30.04.18	CytRx Corporation Highlights NantCell Inc's Aldoxorubicin Abstract Selected for Poster Presentation at the American Society of Clinical Oncology 2018 Annual Meeting (PR Newswire)
18.04.18	CytRx Presents Statistically Significant Breakthrough Data for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates at the American Association for Cancer Research 2018 Annual Meeting (PR Newswire)
09.04.18	CytRx Corporation to Present Breakthrough Data on Albumin Binding Ultra High Potency LADR™ Drug Candidates at the AACR 2018 Conference (PR Newswire)
19.03.18	CytRx Reports 2017 Financial Results (PR Newswire)
16.03.18	CytRx to Present at the 28th Annual Oppenheimer Healthcare Conference (PR Newswire)
15.03.18	CytRx Selects Four New LADR™ Ultra High Potency Drug Candidates for Advancement Toward Clinical Trials (PR Newswire)
12.03.18	CytRx to Hold Year End 2017 Financial Results Conference Call and Webcast on Monday, March 19, 2018 (PR Newswire)
05.03.18	CytRx to Present at the 30th Annual ROTH Conference (PR Newswire)
01.03.18	CytRx Announces Key Addition to Corporate Development Team (PR Newswire)
28.02.18	CytRx Announces Expansion of Pharma Partnering Activities for Its LADR™ Ultra-High Potency Drug Candidates (PR Newswire)
22.02.18	CytRx Announces the Presentation of New LADR™ Candidate Data at the American Association for Cancer Research 2018 Annual Meeting (PR Newswire)
06.02.18	CytRx Corporation to Present at the 2018 BIO CEO & Investor Conference (PR Newswire)
05.02.18	CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell... (PR Newswire)
17.01.18	CytRx Corporation Highlights Dosing of the First Patient in Licensee NantCell Inc. Clinical Trial Investigating Cell-Based Therapy in Combination with Multiple Anti-Cancer Agents, Including... (PR Newswire)
03.01.18	CytRx Corporation to Present at Biotech Showcase 2018 (PR Newswire)
07.12.17	CytRx Corporation Provides Update on Presentations at Upcoming Investor Conferences (PR Newswire)
06.12.17	CytRx Corporation Announces Filing of Key Provisional Patent Applications for Ultra-High Potency LADR™ Drug Candidates (PR Newswire)
27.11.17	CytRx Corporation to Present at Upcoming Investor Conferences (PR Newswire)
17.11.17	CytRx Corporation Regains Nasdaq Listing Compliance (PR Newswire)
13.11.17	CytRx Corporation Provides Business Update and Announces New Shareholder Initiatives (PR Newswire)
08.11.17	CytRx Reports Third Quarter 2017 Financial Results (PR Newswire)
06.11.17	CytRx Announces Strategic Realignment of Clinical Development Team (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu CytRx Corp Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten